{
    "clinical_study": {
        "@rank": "166736", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die.\n\n      PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients\n      who have stage IVB or recurrent cervical cancer."
        }, 
        "brief_title": "Arsenic Trioxide in Treating Patients With Stage IVB or Recurrent Cervical Cancer", 
        "completion_date": {
            "#text": "May 2003", 
            "@type": "Actual"
        }, 
        "condition": "Cervical Cancer", 
        "condition_browse": {
            "mesh_term": "Uterine Cervical Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Evaluate the efficacy of arsenic trioxide in patients with stage IVB or recurrent\n           cervical carcinoma.\n\n        -  Determine the safety of this treatment in these patients.\n\n      OUTLINE: Patients receive arsenic trioxide IV over 1-4 hours on days 1-5. Courses repeat\n      every 28 days in the absence of disease progression or unacceptable toxicity.\n\n      PROJECTED ACCRUAL: A total of 12-37 patients will be accrued for this study over 10-19\n      months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed stage IVB or recurrent cervical carcinoma that is not\n             amenable to standard curative therapies\n\n               -  Squamous carcinoma OR\n\n               -  Adenocarcinoma\n\n          -  Measurable disease\n\n               -  At least 20 mm by conventional techniques OR\n\n               -  At least 10 mm by spiral CT scan\n\n               -  Nonmeasurable disease defined as any of the following:\n\n                    -  Bone disease\n\n                    -  Leptomeningeal disease\n\n                    -  Ascites\n\n                    -  Pleural/pericardial effusion\n\n                    -  Inflammatory breast disease\n\n                    -  Lymphangitis cutis/pulmonis\n\n                    -  Abdominal masses not confirmed or followed by imaging techniques\n\n                    -  Cystic lesions\n\n          -  No active brain metastases\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  17 and over\n\n        Performance status:\n\n          -  Karnofsky 60-100%\n\n        Life expectancy:\n\n          -  Greater than 3 months\n\n        Hematopoietic:\n\n          -  Absolute neutrophil count at least 1,500/mm^3\n\n          -  Platelet count at least 100,000/mm^3\n\n        Hepatic:\n\n          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)\n\n          -  AST and ALT no greater than 2.5 times ULN\n\n        Renal:\n\n          -  Creatinine no greater than 2.0 mg/dL OR\n\n          -  Creatinine clearance at least 50 mL/min\n\n        Cardiovascular:\n\n          -  No cardiac arrhythmias, unstable angina, or conduction abnormalities\n\n          -  No New York Heart Association class III or IV heart disease or clinical evidence of\n             congestive heart failure\n\n          -  Pretreatment QTc less than 500 msec\n\n        Other:\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception during and for 4 months after study\n\n          -  No grade 3 or greater neurologic abnormalities\n\n          -  No history of seizures\n\n          -  No concurrent uncontrolled active infection\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  No more than 2 prior therapies for advanced disease\n\n        Chemotherapy:\n\n          -  No more than 2 prior therapies for advanced disease\n\n          -  At least 4 weeks since prior chemotherapy\n\n        Endocrine therapy:\n\n          -  No more than 2 prior therapies for advanced disease\n\n        Radiotherapy:\n\n          -  No more than 2 prior therapies for advanced disease\n\n          -  At least 4 weeks since prior radiotherapy\n\n        Surgery:\n\n          -  Not specified\n\n        Other:\n\n          -  At least 4 weeks since prior cytotoxic therapy or investigational agents"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "17 Years"
        }, 
        "firstreceived_date": "July 5, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00005999", 
            "org_study_id": "CDR0000068003", 
            "secondary_id": [
                "MSKCC-00018", 
                "NCI-30"
            ]
        }, 
        "intervention": {
            "intervention_name": "arsenic trioxide", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Arsenic trioxide"
        }, 
        "keyword": [
            "recurrent cervical cancer", 
            "stage IVB cervical cancer", 
            "cervical squamous cell carcinoma", 
            "cervical adenocarcinoma"
        ], 
        "lastchanged_date": "June 20, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/MSKCC-00018"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10021"
                }, 
                "name": "Memorial Sloan-Kettering Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase II Study of Arsenic Trioxide (NSC #706363) in Patients With Advanced Cervical Carcinoma", 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "Carol Aghajanian, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00005999"
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Memorial Sloan-Kettering Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2000", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2002"
    }, 
    "geocoordinates": {
        "Memorial Sloan-Kettering Cancer Center": "40.714 -74.006"
    }
}